Literature DB >> 10648386

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

M Federico1, U Vitolo, P L Zinzani, T Chisesi, V Clò, G Bellesi, M Magagnoli, M Liberati, C Boccomini, P Niscola, V Pavone, A Cuneo, G Santini, M Brugiatelli, L Baldini, L Rigacci, L Resegotti.   

Abstract

Patients (n-987) with a histologically confirmed diagnosis of follicular lymphoma were studied with the aim of developing a prognostic model specifically devised for this type of lymphoma. We collected information on age, sex, Ann Arbor stage, number of extranodal disease sites, bone marrow (BM) involvement, bulky disease, B symptom criteria (fever, night sweats, and weight loss), performance status (PS), serum lactate dehydrogenase (LDH) level, serum albumin level, hemoglobin level, and erythrocyte sedimentation rate (ESR). In the training sample of 429 patients with complete data, multivariate analysis showed that age, sex, number of extranodal sites, B symptoms, serum LDH level, and ESR were factors predictive for overall survival. Using these 6 variables, a prognostic model was devised to identify 3 groups at different risk. The 5- and 10-year survival rate was 90% and 65% for patients at low risk, respectively; 75% and 54% for patients at intermediate risk; and 38% and 11% for those at high risk (log-rank test, 86.62; P <. 0001). The model was also predictive (P =.0001) in the validation sample of 265 patients with complete data only for the 6 variables used in the development of the model and even in the group of 210 patients from the validation sample uniformly treated with doxorubicin-containing regimens (P =.0001). The prognostic model appears to be very useful in identifying patients with follicular lymphoma at low, intermediate, or high risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648386

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.

Authors:  Chiara Lobetti-Bodoni; Barbara Mantoan; Luigia Monitillo; Elisa Genuardi; Daniela Drandi; Daniela Barbero; Elisa Bernocco; Mario Boccadoro; Marco Ladetto
Journal:  Ther Adv Hematol       Date:  2013-06

3.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors:  Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 4.  Gastrointestinal follicular lymphoma: review of the literature.

Authors:  Shuji Yamamoto; Hiroshi Nakase; Kouhei Yamashita; Minoru Matsuura; Mariko Takada; Chiharu Kawanami; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2010-01-20       Impact factor: 7.527

Review 5.  Role of hematopoietic stem cell transplant in the management of follicular lymphoma.

Authors:  Matthew Foster; Don A Gabriel; Thomas Shea
Journal:  Oncologist       Date:  2009-06-26

Review 6.  Prognostic factors in low-grade non-Hodgkin lymphomas.

Authors:  Massimo Federico; Stefano Molica; Monica Bellei; Stefano Luminari
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

7.  Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

Authors:  Christian Taverna; Giovanni Martinelli; Felicitas Hitz; Walter Mingrone; Thomas Pabst; Lidija Cevreska; Auro Del Giglio; Anna Vanazzi; Daniele Laszlo; Johann Raats; Daniel Rauch; Daniel A Vorobiof; Andreas Lohri; Christine Biaggi Rudolf; Stéphanie Rondeau; Corinne Rusterholz; Ingmar A F M Heijnen; Emanuele Zucca; Michele Ghielmini
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

8.  A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Authors:  Emmanuel Bachy; Matthew J Maurer; Thomas M Habermann; Bénédicte Gelas-Dore; Delphine Maucort-Boulch; Jane A Estell; Eric Van den Neste; Réda Bouabdallah; Emmanuel Gyan; Andrew L Feldman; Joan Bargay; Alain Delmer; Susan L Slager; Maria Gomes da Silva; Olivier Fitoussi; David Belada; Hervé Maisonneuve; Tanin Intragumtornchai; Stephen M Ansell; Thierry Lamy; Peggy Dartigues; Brian K Link; John F Seymour; James R Cerhan; Gilles Salles
Journal:  Blood       Date:  2018-04-17       Impact factor: 22.113

9.  Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

Authors:  Chadi Nabhan; Xiaolei Zhou; Bann-Mo Day; Keith Dawson; Andrew D Zelenetz; Jonathan W Friedberg; James R Cerhan; Brian K Link; Christopher R Flowers
Journal:  Am J Hematol       Date:  2016-05-24       Impact factor: 10.047

10.  Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.

Authors:  Weiyun Z Ai; Robert Tibshirani; Behnaz Taidi; Debra Czerwinski; Ronald Levy
Journal:  Blood       Date:  2009-04-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.